FDA Uses New Process to Approve Ribociclib Extensions FDA Uses New Process to Approve Ribociclib Extensions

The agency has used two new programs that allow real-time review of clinical data to approve extensions to the use of ribociclib in breast cancer.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news